Hospital 366 Days · Case No. 36
The hospital’s year does not end at 365. It runs to 366, and keeps going.
Call her Nell. Age, location, and any potentially identifying facts have been changed. The clinical pattern is a composite reconstructed from cases hospitals see repeatedly, and it does not represent any specific patient.
A diabetic foot ulcer not healing after a full course of antibiotics is rarely a story about a patient who skipped doses. Nell arrived with an empty pill bottle and a story about doing everything right. She had taken every antibiotic exactly as written, on schedule, to the last dose, and the ulcer on her foot was the same size it had been a month earlier. This case file is about the gap between finishing the treatment and being treated, and about how a wound that will not close becomes the first mile of a road toward amputation.
Call her Nell. She was 63. It took two nurses to move her from the wheelchair to the exam table, because her left foot could not touch the floor. It had been that way for a month.
She brought the pill bottle with her, and it was empty. The label read linezolid 600 mg, twice a day, fourteen days. She had taken every dose exactly as written. “I finished all of it,” she said. “And it’s the same.”
Pain was 10 out of 10. No fever. No chills. The wound leaked a clear fluid, and now and then something thicker. She had been discharged from this same hospital 24 days earlier.
Who Nell Was Before the Wheelchair
Nell had lived with type 2 diabetes for twelve years, and her blood sugar control came and went. After a stent went into a coronary artery, she stayed on the antiplatelet drug clopidogrel, sold as Plavix.
The real root of the ulcer was blood flow. The superficial femoral artery in her left leg was blocked, and blood was not reaching the foot the way it should. A place that blood does not reach does not heal. That was where it started.
When she was admitted a month earlier, the ulcer was already infected. Surgeons cut away the dead tissue in a procedure called debridement. Three days later they reopened the blocked artery, widening it with a balloon and cracking the hardened, calcified vessel wall with sound waves, a technique called intravascular lithotripsy.
The culture taken from the wound grew two organisms. Both belonged to the same family. Which family, and why it turned out to matter, comes later in this file.
She spent ten days on intravenous antibiotics. What she carried home was a fourteen-day supply of oral linezolid. No wound care clinic appointment was booked. Nell called on her own, and the answer she got was that someone would be in touch. No one was.
That Month, In Order
| Time Point | What Happened | Signal |
|---|---|---|
| Day 1 | Transferred from a small outlying ER, admitted | Baseline |
| Day 4 | Debridement, wound culture taken | Workup |
| Day 7 | Artery reopened: angioplasty plus lithotripsy | Intervention |
| Day 11 | Discharge, 14 days of oral linezolid, wound care “by phone” | Follow-up gap |
| Days 12 to 25 | Medication finished on schedule, ulcer unchanged, no call | No response |
| Days 26 to 34 | Pain climbing, life reduced to a wheelchair indoors | Deterioration |
| Day 35 | Back to the emergency room | Readmission |
She did everything the discharge paper asked. The paper had asked for the wrong thing.
What the Admitting Team Found
The ulcer was the same size it had been a month before. The drainage was mostly clear, with intermittent pus, and the skin around it was red and swollen. Vital signs were stable, and there was no fever. This was not sepsis. It simply was not healing.
She could not bear weight, and she reported none of the systemic warning signs: no fever, no chills, no body aches, no chest pain, no shortness of breath, no nausea, no vomiting.
The admitting team left one question in the chart. Did the antibiotic sent home at discharge actually cover the organisms that grew in the culture? The answer, waiting in the microbiology report, is where this file turns.
Reading the Clinical Markers
| Marker | Nell’s Value | Reading |
|---|---|---|
| Blood sugar control (A1c) | Inconsistent | Works against blood flow and healing |
| Ulcer duration | 35 days, no change in size | Past the healing-failure threshold |
| Pain score | 10 / 10 | Severe |
| Temperature | Normal | Normal, but read with caution |
| Culture vs antibiotic coverage | Two gram-negative vs a gram-positive drug | Mismatch |
| Revascularization | Procedure complete | Recheck flow and re-narrowing |
| Wound care follow-up | None | Missing |
Two rows carry the weight of this case. The mismatch between the organisms and the drug is one, and it is explained in the reviewer’s notes below. The missing appointment is the other, and it is the one nobody ordered, nobody charted, and nobody caught.
Plain-Language Reference
| Term | What It Means in Plain Language |
|---|---|
| Debridement | Cutting away dead or infected tissue to give a wound a clean base to heal from. |
| Superficial femoral artery | A major artery running down the thigh that carries blood into the lower leg. |
| Intravascular lithotripsy | Using sound waves to break up calcium hardening a vessel wall so the artery can be widened. |
| Gram-positive vs gram-negative | The basic split of bacteria by cell wall structure, and the starting point for choosing an antibiotic. |
| Linezolid | An oral antibiotic for gram-positive bacteria, aimed at MRSA and VRE. |
| Pseudomonas aeruginosa | A gram-negative bacterium common in water and soil, and a frequent resident of chronic wounds. |
| Alcaligenes faecalis | A gram-negative organism from water and soil, found less often, in chronic wounds and weakened immune systems. |
| Clopidogrel | An antiplatelet drug that prevents clots after a stent. |
| Fluoroquinolone | A class of antibiotics that includes the only oral drugs with reliable activity against Pseudomonas. |
| Wound care clinic | An outpatient clinic that manages wounds that are not healing. |
| Osteomyelitis | Infection that has reached the bone, which must be ruled out when an ulcer lingers. |
| Probe-to-bone test | A bedside test where a blunt probe is passed into the ulcer to feel for bone. |
| Microcirculation | Blood flow through the smallest vessels, which antibiotics rely on to reach tissue. |
| Prior authorization | An insurer’s requirement to approve a service before it is provided or paid for. |
From the Reviewer · Eleanor Hayes, M.D.
(A) The culture result is the map
In cases like this, when two gram-negative organisms grow and the drug in the patient’s hand is gram-positive only, the first question is a plain one: what was that drug aimed at? There is a reasonable clinical read where the intravenous course already treated the gram-negatives and the oral drug was meant to cover a gram-positive skin reinfection. That judgment is not unheard of. Either way, in this pattern the reason belongs in the discharge summary, and often it is not there.
(B) What linezolid covers, and what it does not
In cases like this, the spectrum tells the story. Linezolid covers MRSA and VRE. It does not cover Pseudomonas or Alcaligenes. The natural follow-up is why an oral anti-pseudomonal drug was not given from the start, and the answer is that the only oral drugs with reliable activity against Pseudomonas are the fluoroquinolones, which in practice means ciprofloxacin and levofloxacin. Ciprofloxacin is the more dependable of the two and has to be dosed high, at 750 mg twice a day rather than a low dose. Levofloxacin is generally weaker against Pseudomonas milligram for milligram.
(C) The resistance problem
In cases like this, resistance is why the oral option is not a simple substitute. Fluoroquinolone resistance in Pseudomonas is substantial and varies by region and year. United States surveillance has tracked ciprofloxacin resistance climbing from about 15 percent in the early 1990s to 30 percent or higher by the 2000s, with some series reporting above 40 percent. That makes it hard to use empirically, without susceptibility results in hand, which is exactly why intravenous treatment in the hospital was the sound call, and exactly why the gram-positive-only discharge drug raises the question it does.
(D) An uncommon organism
In cases like this, the second name on the culture matters too. Alcaligenes faecalis is a water and soil organism that shows up, uncommonly, in chronic wounds and weakened immune systems. It is not common, and the antibiotic options against it are limited, which is one more reason the discharge plan should have been built on the culture rather than around it.
(E) No blood flow, no delivery
In cases like this, the antibiotic question sits on top of a circulation question. An antibiotic cannot reach tissue that blood does not reach. Even after the superficial femoral artery is reopened, microcirculation takes time to recover, and re-narrowing has to be watched for. A drug that is correct on paper still fails if it cannot arrive.
(F) Clopidogrel and the vascular work
In cases like this, two competing needs run at once. Antiplatelet drugs should not be casually stopped after a vascular procedure, and yet the bleeding from debridement has to be managed at the same time. Balancing both is the ordinary reality for this kind of patient, not a complication that signals something went wrong.
(G) Pain of 10 with a normal temperature
In cases like this, a missing fever is not a missing infection. In patients with diabetes, neuropathy and a blunted immune response mean fever can arrive late, or not at all. Severe pain in a wound that will not close is its own signal, and a normal temperature does not cancel it.
(H) An ulcer unchanged for 35 days
In cases like this, an ulcer that has not changed for that long is an alarm in itself. Guidelines hold that after at least four weeks of standard care, an ulcer that has not shrunk by 50 percent should be treated as a healing failure, with adjunctive treatment considered. The basis is a well-known finding: whether an ulcer drops 50 percent in area by week four predicts whether it heals by week twelve. In that study, patients above the mark healed at 58 percent, and those below it at 9 percent.
(I) Rule out osteomyelitis
In cases like this, infection reaching the bone has to be excluded. It can sit under any diabetic foot ulcer, and especially one that has lasted for weeks, or is broad or deep, or sits over a bony prominence. Nell’s ulcer fits that profile. The order of testing is set: first a probe-to-bone test and a plain X-ray, then MRI if doubt remains. Probe-to-bone detects osteomyelitis with a sensitivity of 0.87 and a specificity of 0.83, a simple but useful first gate.
(J) The gap itself
In cases like this, the wound care appointment is something that should be confirmed before discharge, not left to a phone call that may never come. “Someone will call” often means no one calls. If there is one thing a patient can do, it is to check, on the spot, that a dated appointment is actually written on the discharge summary. No date means no appointment. This series has watched a foot go the same direction in a case about a patient on dialysis, and watched a man who took his medication exactly as told arrive at the same kind of bad ending.
(K) A closing thought
In cases like this, the road to an amputation is rarely one large event. It is usually a few quiet gaps laid end to end: a drug chosen without the culture, a follow-up left to a phone call, a wound that stops being anyone’s specific responsibility the moment the patient walks out the door. An antibiotic is a drug chosen to target a specific organism. Choose it without looking at which organism, and how faithfully the patient finished the course changes nothing at all.
What It Costs, and Who Pays
A diabetic foot ulcer is one of the quiet, large line items in American health spending. The incremental cost of caring for a Medicare patient with a foot ulcer runs roughly $12,000 a year above diabetes alone, and once vascular procedures enter the picture it climbs well beyond that. Nell had debridement, angioplasty, and lithotripsy in a single admission, so she sat at the upper end of the range.
Zoom out, and the national burden of diabetic foot ulcers is estimated at $9 billion to $13 billion a year. More than half of these ulcers become infected, and roughly one in six leads to an amputation.
Narrow it to Medicare and the numbers sharpen. A Medicare beneficiary with a diabetic foot ulcer costs about $33,000 a year. A beneficiary who reaches a lower-limb amputation costs about $52,000 a year. Much of the distance from $33,000 to $52,000 begins with a single missed appointment, the kind Nell was living inside.
Assume Nell is enrolled in Medicare Advantage. A 2026 rule change is worth naming here. As of January 1, 2026, the CMS interoperability and prior authorization final rule took effect, cutting the standard prior authorization decision window from as long as 14 days down to 7, and requiring urgent requests to be answered within 72 hours. Denials now have to state a specific reason, and the finalized 2026 Medicare Advantage rule pushes plans to honor medical necessity decisions and closes gaps in the appeals process.
Here is the catch. Those rules govern how fast a plan approves or denies something. Nell’s problem was neither an approval nor a denial. The appointment was simply never made, and there is nothing to approve or deny in the words “someone will be in touch.” The rules moved in a better direction, and the gap they do not aim at stayed exactly where it was.
Tools for Reading Your Own Numbers
Before a clinic runs its own workup, three calculators that frame your lab, cardiovascular, and longevity numbers against age-matched references.
· Blood Work Decoder (Read Your Own Labs)
· Heart Age Calculator (Cardiovascular Age Estimate)
· Life Calculator (Longevity Estimate)
This file closes with Nell readmitted. Intravenous antibiotics started again, and vascular surgery went back to reassessing her. This time the wound care appointment was confirmed, with a date, before discharge. Whether it ends in an amputation is still open.
The conclusion of this case is a map rather than a verdict. A patient can finish every pill she is handed and still go untreated, because the treatment was aimed at the wrong target and the follow-up was aimed at no one. Nell held up her end completely. The gaps were on the other side of the counter, in a discharge summary that did not explain itself and an appointment that was never made.
She did everything she was told. That may be the most uncomfortable fact in this file.
Names and identifying details in this case have been altered to protect privacy. The case is a composite reconstructed from publicly reported clinical patterns and does not represent any specific patient. This content is for general information only and is not medical advice, and reading it creates no provider-patient relationship. If you have a diabetic foot ulcer that is not improving, ask your clinician whether the wound has been cultured, whether the antibiotic matches the result, and whether a dated wound care appointment is written on your discharge paperwork before you leave.
Take care of yourself. Nobody else will do it for you.
Wilbur P is the editor of Manclub, leading coverage across health and life. His work is research-driven and built on primary sources a reader can verify – written for men in the second half of life who would rather know than believe. Based in Florida, still learning and still in the fight. Corrections, questions, story tips: [email protected].